IDEXX Laboratories, Inc. $IDXX Stock Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors reduced its IDEXX Laboratories stake by 2.0% in the third quarter, selling 2,361 shares and retaining 114,834 shares worth approximately $60.0 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly EPS of $4.27, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company set fiscal 2026 EPS guidance at $14.69–$14.94.
• Analysts maintain a generally positive outlook, with seven Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $744.09, well above the stock’s reported $560.38 opening price.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 114,834 shares of the company's stock after selling 2,361 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned about 0.15% of IDEXX Laboratories worth $59,966,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Aries Wealth Management purchased a new position in shares of IDEXX Laboratories during the third quarter worth $1,670,000. Live Oak Investment Partners grew its stake in shares of IDEXX Laboratories by 1.5% in the third quarter. Live Oak Investment Partners now owns 2,516 shares of the company's stock valued at $1,314,000 after buying an additional 38 shares in the last quarter. Signaturefd LLC grew its stake in shares of IDEXX Laboratories by 21.4% in the third quarter. Signaturefd LLC now owns 1,964 shares of the company's stock valued at $1,026,000 after buying an additional 346 shares in the last quarter. Citizens Financial Group Inc. RI raised its holdings in shares of IDEXX Laboratories by 51.1% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 3,400 shares of the company's stock valued at $1,776,000 after buying an additional 1,150 shares during the period. Finally, One Wealth Capital Management LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth about $699,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX opened at $560.38 on Monday. The business has a fifty day moving average price of $532.69 and a 200 day moving average price of $551.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The stock has a market capitalization of $44.15 billion, a price-to-earnings ratio of 39.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. IDEXX Laboratories's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IDXX. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. UBS Group increased their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating for the company in a research note on Friday, October 16th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $744.09.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.